Fisher Asset Management LLC Buys 30,612 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Fisher Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 18.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 198,696 shares of the biopharmaceutical company’s stock after acquiring an additional 30,612 shares during the quarter. Fisher Asset Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $4,570,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after acquiring an additional 29,984 shares during the last quarter. Creative Planning bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $454,000. American Century Companies Inc. bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $366,000. M&T Bank Corp grew its holdings in Ultragenyx Pharmaceutical by 19.7% during the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 1,192 shares during the last quarter. Finally, Amundi grew its holdings in Ultragenyx Pharmaceutical by 1,560.4% during the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock worth $3,913,000 after acquiring an additional 93,189 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $23.26 on Friday. The company has a market capitalization of $2.29 billion, a P/E ratio of -3.81 and a beta of 0.39. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.29 and a 52-week high of $42.37. The company’s 50 day moving average price is $23.36 and its 200-day moving average price is $25.84.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The firm had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. During the same quarter last year, the firm posted ($1.57) EPS. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.62 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 54,404 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $1,240,411.20. Following the transaction, the chief executive officer owned 658,994 shares in the company, valued at approximately $15,025,063.20. The trade was a 7.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Howard Horn sold 8,409 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.70, for a total transaction of $190,884.30. Following the completion of the transaction, the chief financial officer owned 86,669 shares in the company, valued at $1,967,386.30. This trade represents a 8.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 117,262 shares of company stock worth $2,687,403. Company insiders own 5.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Wall Street Zen lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Barclays reduced their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th. Wells Fargo & Company boosted their target price on shares of Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. reduced their target price on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a report on Thursday, March 12th. Finally, The Goldman Sachs Group lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.56.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.